Seborrheic Dermatitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for seborrheic dermatitis. 241 active patents protecting 10 drugs from 8+ originators. First major cliff: 2027. Daily refresh.

10
Approved drugs
241
Active US patents
63/100
Avg vulnerability
$2.9B
Annual revenue covered

Originators in Seborrheic Dermatitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Teva Pharm 118 patents Merck & Co. 42 patents Mayne Pharma 38 patents Generic (originally Merck/Upjohn) 29 patents Fougera Pharms 8 patents Eurofarma 4 patents Padagis Us 1 patents Taro 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating seborrheic dermatitis. Each bar = one year. Y-axis scaled to peak year (40 patents).

3
26
7
27
11
28
11
29
16
30
40
31
8
32
4
33
31
34
16
35
11
36
3
37
3
38
25
39
38
40
12
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cutivate
FLUTICASONE PROPIONATE
 Teva Pharm 118 58 $69M 2026-08-26
Benzamycin
BENZOYL PEROXIDE
 Mayne Pharma 38 70 — 2028-02-03
Elocon
MOMETASONE FUROATE
 Merck & Co. 22 44 — 2026-11-29
Diprolene
BETAMETHASONE DIPROPIONATE
 Merck & Co. 20 62 — 2027-09-27
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Temovate
CLOBETASOL PROPIONATE
 Fougera Pharms 8 50 — 2028-11-05
Derma-Smoothe/Fs
FLUOCINOLONE ACETONIDE
 Eurofarma 4 72 — 2027-08-12
Verdeso
DESONIDE
 Padagis Us 1 80 $2.8B 2027-08-13
Topicort
DESOXIMETASONE
 Taro 1 83 — 2028-09-01

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9849027 Derma-Smoothe/Fs method of use 88 2028-11-07
7998108 Derma-Smoothe/Fs method of use 83 2028-01-12
9868103 Benzamycin method of use 83 2028-08-08
12070629 Benzamycin method of use 81 2030-12-30
12083270 Cutivate method of use 81 2031-04-04
7500444 Cutivate other 80 2026-08-26
7500444 Cutivate other 80 2026-08-26
8460641 Verdeso method of use 80 2027-08-13
8277780 Topicort method of use 80 2028-09-01
9868103 Benzamycin method of use 75 2028-08-08

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12303635 Elocon composition of matter 0 2039-04-08
10537585 Decadron formulation 25 2037-12-18
9855334 Temovate formulation 25 2035-03-11
10159683 Decadron formulation 25 2034-05-23
10406332 Elocon formulation 25 2034-03-13
10799642 Decadron formulation 31 2032-05-11
8763222 Elocon formulation 31 2032-02-08
8409606 Decadron formulation 31 2030-05-14
11679210 Elocon formulation 33 2038-09-03
10561672 Elocon formulation 33 2034-09-04

Related